These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 16550602)

  • 1. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL.
    Butler LM; Liapis V; Bouralexis S; Welldon K; Hay S; Thai le M; Labrinidis A; Tilley WD; Findlay DM; Evdokiou A
    Int J Cancer; 2006 Aug; 119(4):944-54. PubMed ID: 16550602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.
    Shankar S; Singh TR; Fandy TE; Luetrakul T; Ross DD; Srivastava RK
    Int J Mol Med; 2005 Dec; 16(6):1125-38. PubMed ID: 16273296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.
    Thai le M; Labrinidis A; Hay S; Liapis V; Bouralexis S; Welldon K; Coventry BJ; Findlay DM; Evdokiou A
    Cancer Res; 2006 May; 66(10):5363-70. PubMed ID: 16707463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
    Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N
    BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
    Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
    Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis.
    Lakshmikanthan V; Kaddour-Djebbar I; Lewis RW; Kumar MV
    Int J Cancer; 2006 Jul; 119(1):221-8. PubMed ID: 16450389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
    Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
    Ng CP; Zisman A; Bonavida B
    Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
    Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA
    Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells.
    Nakata S; Yoshida T; Horinaka M; Shiraishi T; Wakada M; Sakai T
    Oncogene; 2004 Aug; 23(37):6261-71. PubMed ID: 15208660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
    Ravi R; Bedi A
    Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL.
    Pathil A; Armeanu S; Venturelli S; Mascagni P; Weiss TS; Gregor M; Lauer UM; Bitzer M
    Hepatology; 2006 Mar; 43(3):425-34. PubMed ID: 16583461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.
    Sonnemann J; Kumar KS; Heesch S; Müller C; Hartwig C; Maass M; Bader P; Beck JF
    Int J Oncol; 2006 Mar; 28(3):755-66. PubMed ID: 16465382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells.
    He Q; Luo X; Huang Y; Sheikh MS
    Oncogene; 2002 Sep; 21(39):6032-40. PubMed ID: 12203115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
    Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
    Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SAHA/TRAIL combination induces detachment and anoikis of MDA-MB231 and MCF-7 breast cancer cells.
    Lauricella M; Ciraolo A; Carlisi D; Vento R; Tesoriere G
    Biochimie; 2012 Feb; 94(2):287-99. PubMed ID: 21835222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis.
    Evdokiou A; Bouralexis S; Atkins GJ; Chai F; Hay S; Clayer M; Findlay DM
    Int J Cancer; 2002 Jun; 99(4):491-504. PubMed ID: 11992538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade.
    Reddy RM; Yeow WS; Chua A; Nguyen DM; Baras A; Ziauddin MF; Shamimi-Noori SM; Maxhimer JB; Schrump DS; Nguyen DM
    Apoptosis; 2007 Jan; 12(1):55-71. PubMed ID: 17136498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation.
    Ziauddin MF; Yeow WS; Maxhimer JB; Baras A; Chua A; Reddy RM; Tsai W; Cole GW; Schrump DS; Nguyen DM
    Neoplasia; 2006 Jun; 8(6):446-57. PubMed ID: 16820090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
    Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC
    Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.